Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Alzheimer's disease (AD) is characterized by amyloid-β (Aβ) accumulation, autophagic lysosomal pathway (ALP) dysfunction, mitochondrial abnormalities, and neuroinflammation. Physical exercise (PE) protects against AD, but its molecular mechanisms remain unclear. We hypothesize that PE-mediated upregulation of REV-ERBα and TFEB pathways mitigates AD-related dysfunctions. Acute effects of FK506, a calcineurin inhibitor, were assessed as a TFEB suppressor in mice subjected to aerobic exercise. Chronic treadmill training (8 weeks, 4 sessions/week) was performed in APP/PS1 mice to evaluate hippocampal adaptations through functional tests, imaging, and molecular analyses. Acute FK506 administration inhibited Ppp3ca and Ppp3r1 expression without altering Tfeb levels. Chronic PE improved aerobic capacity, strength, coordination, and memory, promoted neuronal survival, and decreased Aβ levels in APP mice. It also elevated REV-ERBα protein and Nr1 d1 expression in wild-type and APP mice, increased ALP activity, and reduced abnormal mitochondria in the hippocampus of APP mice. A positive correlation between REV-ERBα and Nr1 d1 levels was observed in the 2-min NOR test. Public RNA-seq data revealed lower NR1D1 mRNA in extracellular vesicles from the human frontal cortex of AD patients compared to controls. PE prevents cognitive decline in APP/PS1 mice, enhancing memory, physical performance, and hippocampal health. These benefits are associated with ALP activation, mitochondrial improvements, and reduced neuroinflammation. REV-ERBα may mediate these protective effects, but further studies using pharmacological and genetic models are needed to confirm its role.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-025-05066-2DOI Listing

Publication Analysis

Top Keywords

app mice
12
exercise protects
8
alzheimer's disease
8
mitochondrial abnormalities
8
app/ps1 mice
8
mice
6
chronic exercise
4
protects cognitive
4
cognitive deficits
4
deficits alzheimer's
4

Similar Publications

Background: Synaptic dysfunction and synapse loss occur in Alzheimer's disease (AD). The current study aimed to identify synaptic-related genes with diagnostic potential for AD.

Methods: Differentially expressed genes (DEGs) were overlapped with phenotype-associated module selected through weighted gene co-expression network analysis (WGCNA), and synaptic-related genes.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) patients and animal models exhibit an altered gut microbiome that is associated with pathological changes in the brain. Intestinal miRNA enters bacteria and regulates bacterial metabolism and proliferation. This study aimed to investigate whether the manipulation of miRNA could alter the gut microbiome and AD pathologies.

View Article and Find Full Text PDF

This study investigated the learning strategy preferences of 11-month-old APP/PS1 double transgenic (Tg) mice, a well-established murine model of Alzheimer's disease (AD). APP/PS1 Tg and non-Tg control mice were serially trained in visual and hidden platform tasks in the Morris water maze. APP/PS1 Tg mice performed poorly in visual platform training compared with non-Tg mice but performed as well as non-Tg mice in hidden platform training.

View Article and Find Full Text PDF

In this study, we investigated the therapeutic potential of calycosin (from Astragalus) in Alzheimer's disease (AD), focusing on ferroptosis modulation. APP/PS1 mice received 40 mg/kg calycosin for 3 months. Cognitive function was assessed via Morris water maze test.

View Article and Find Full Text PDF

Neuroavailable peptides from hempseed protein hydrolysates reduce hippocampal inflammation and glial activation in a scopolamine-induced Alzheimer's disease.

Biomed Pharmacother

September 2025

Department of Medical Biochemistry, Molecular Biology, and Immunology, School of Medicine, University of Seville, Spain; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, 41013, Spain. Electronic address:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairment, synaptic dysfunction, and neuronal loss. Neuroinflammation, driven by the activation of microglia and astrocytes, is a key contributor to AD pathology, amplifying oxidative stress and amyloid-β toxicity. Modulation of neuroinflammatory pathways thus represents a promising therapeutic strategy.

View Article and Find Full Text PDF